Abbott Medical is recalling its Proclaim neurostimulation systems and Infinity IPGs after receiving complaints that users were unable the exit the magnetic resonance imaging (MRI) mode.

On 13 September, the US Food and Drug Administration (FDA) identified it as a Class I recall meaning it has a risk of causing serious injury or death.

There have been 186 reported incidents of faulty devices and 76 cases of injuries. So far, no deaths have been reported.

The devices at the centre of the recall are designed to deliver low-intensity electrical impulses to nerve structures. The products affected include the Proclaim XR and Proclaim Plus implantable pulse generators (IPGs), used for Spinal Cord Stimulation (SCS). The Proclaim DRG IPG, used for Dorsal Root Ganglion (DRG) stimulation and the Infinity IPGs, used for Deep Brain Stimulation (DBS).

They work with a Patient Controller (PC) device using an app on an iPhone or iPod which connects to the IPG through Bluetooth. It has the option to disable the delivery of therapy when a patient receives an MRI but there have been reports of users unable to exit the MRI mode as PC’s are unable to connect or communicate with the IPG while in MRI mode. This occurred following an update of iOS systems on apple products.

Those with affected IPGs will need to replace it with a new device and may require surgery.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Abbott Medical issued an Urgent ³Ô¹ÏºÚÁÏÍø correction letter on the 18th of July to all the affected implanting surgeons. The letter recommends patients not to delete the paired Bluetooth connection between their IPG and PC.  It also advises patients to update the PC app before entering the MRI mode with the â€œPatient Controller NR – US†application from the Apple App Store.

Abbott’s recent Class I recall is just the latest in a long list of device issues this year. Just this month, the FDA tagged Mallinckrodt’s one-way valve recall as Class I and handed Getinge’s Cardiosave Hybrid and Rescue Intra-aortic balloon pumps the same certification after several issues emerged about the troubled device.

³Ô¹ÏºÚÁÏÍø Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious ³Ô¹ÏºÚÁÏÍø Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now